CD274 and neoplasm: With the lack of reliable predictive biomarkers or clear discontinuation guidelines, clinicians rely on clinical and biological features such as programmed death-ligand 1 (PD-L1) expression, smoking status, tumor histology, and baseline tumor burden for (de)escalation proposal.